Semaglutide 7.2mg achieved 20.7% weight loss in STEP UP obesity trial

17 January 2025

Danish diabetes and obesity giant Novo Nordisk (NOV: N) today announced headline results from STEP UP, a Phase IIIb trial in the global STEP program, in a further bid to cement its dominance of the weight-management sector.

However, investors were not too impressed, sending the firm’s shares down 3.8% to 578.00 kroner as markets came to a close.

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2mg compared to semaglutide 2.4mg and placebo, all administered once weekly. The trial included 1,407 randomized adults with obesity. All treatment arms were in conjunction with lifestyle intervention.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK